Ocular Oncology Unit, "Fondazione Policlinico Universitario A. Gemelli, IRCCS", Rome, Italy.
Catholic University "Sacro Cuore", Largo A. Gemelli 8, Rome, Italy.
J Cancer Res Clin Oncol. 2023 Jul;149(8):4305-4314. doi: 10.1007/s00432-022-04241-5. Epub 2022 Sep 8.
Since there is a lack of clear information regarding the benefit to combine supportive therapies (such as artificial tears) to mitomycin C (MMC) in the treatment of ocular surface neoplasia, the primary purpose of the study was to evaluate hyaluronic acid eye drops and hyaluronic acid-conjugated lactobionic acid (LACTOyal FREE) eye drops as supportive therapy.
Retrospective evaluation of patients with ocular surface squamous neoplasia or conjunctival melanocytic tumor treated with MMC, who had used also artificial tears as supportive treatment. A 6-month follow-up with evaluation of subjective and objective tests for ocular surface integrity was conducted.
A total of 35 patients were analyzed, most of them with squamous disease (71.4%). The break-up time (BUT), Ocular Surface Disease Index (OSDI) and Schirmer test values showed a significant difference at any time point with overall population. No statistical difference was found among subgroups (Lactoyal vs No Lactoyal).
The use of an ancillary therapy based on hyaluronic acid allows to improve both subjective and objective ocular parameters, reducing MMC induced adverse effects. Meantime, hyaluronic acid-conjugated lactobionic acid eye drops highlighted the same advantages with a more positive trend in OSDI results.
由于缺乏关于联合支持疗法（如人工泪液）与丝裂霉素 C（MMC）联合治疗眼表肿瘤益处的明确信息，本研究的主要目的是评估透明质酸滴眼液和透明质酸结合乳糖酸（LACTOyal FREE）滴眼液作为支持疗法。
回顾性评估接受 MMC 治疗的眼表鳞状上皮肿瘤或结膜黑色素瘤患者，这些患者也使用了人工泪液作为支持治疗。进行了 6 个月的随访，评估眼表完整性的主观和客观测试。
共分析了 35 例患者，其中大多数为鳞状疾病（71.4%）。在任何时间点，所有患者的泪膜破裂时间（BUT）、眼表疾病指数（OSDI）和 Schirmer 试验值均有显著差异。但在亚组（含乳糖酸组与不含乳糖酸组）之间未发现统计学差异。
基于透明质酸的辅助治疗可改善主观和客观眼表参数，减少 MMC 引起的不良反应。同时，透明质酸结合乳糖酸滴眼液在 OSDI 结果方面表现出相同的优势，且呈更积极的趋势。
